Aims/Introduction: The present multicenter, prospective, controlled, open and randomized three-arm parallel study was designed to compare the effects of linagliptin with those of metformin on endothelial function. Materials and Methods: Type 2 diabetes patients treated with 750 mg of metformin (hemoglobin A1c ≥6.0% and <8.0%, n = 96) were randomized to continue metformin 750 mg/day (control group, n = 29), metformin at 1,500 mg/day (metformin group, n = 26) and metformin 750 mg/day supplemented with linagliptin 5 mg/day (linagliptin add-on group, n = 29) and treated for 16 weeks. Vascular endothelial function was evaluated by flow-mediated dilation. The primary end-point was changes in flow-mediated dilation at 16 weeks relative to baseline. Results: Linagliptin significantly improved flow-mediated dilation from baseline (4.9 -2.7%) to 16 weeks (6.3 -2.7%, P < 0.05), whereas the other groups did not show any changes. Hemoglobin A1c at 16 weeks was significantly lower in the metformin and linagliptin add-on groups compared with the control (6.6 -0.6%, 6.5 -0.5% and 7.0 -0.6%, respectively). Single and multiple regression analyses showed that apolipoprotein B correlated significantly with change in flow-mediated dilation, and apolipoprotein B was decreased only in the linagliptin add-on group (-6.0 -11.3 mg/dL, P < 0.01). Conclusions: Linagliptin for 16 weeks improved endothelial function with a modest improvement in glycemic control. This effect was mediated, at least in part, by reduction in apolipoprotein B. Linagliptin has a protective role on endothelial function in patients with type 2 diabetes with moderate hyperglycemia.
INTRODUCTION
Type 2 diabetes mellitus is one of the major factors for progression of atherosclerosis and development of cardiovascular diseases 1, 2 . In addition to lowering blood glucose level, prevention of cardiovascular diseases is crucial for patients with type 2 diabetes mellitus. It is important to screen cardiovascular events at an early stage. Recently, it has been reported that vascular endothelial dysfunction is the initial stage of atherosclerosis, and thought to be the earliest predictor for future cardiovascular events in patients with type 2 diabetes mellitus 3 . Various non-invasive methods are currently available for early detection of atherosclerosis. Among them, the flow-mediated dilation (FMD) is an established method for evaluating vascular endothelial function 4 , and the cardio-ankle vascular index (CAVI), which measures vascular stiffness, is also used as an early index of atherosclerosis [5] [6] [7] . To date, various antidiabetic oral agents with different mechanisms are available. The American Diabetes Association and the European Association for the Study of Diabetes recommend the use of metformin, which prevents cardiovascular events, as the first-line drug [8] [9] [10] . Dipeptidyl peptidase-4 (DPP-4) inhibitors, which are other antidiabetic oral agents, lower blood glucose by preventing the inactivation of incretin hormones by DPP-4. They are widely available for the treatment of type 2 diabetes mellitus, and some randomized clinical trials have shown non-inferiority of DPP-4 inhibitors on cardiovascular events in patients with type 2 diabetes mellitus compared with placebo control [11] [12] [13] , however; some participants of these studies already had a history of cardiovascular diseases. To elucidate the true effect of DPP-4 inhibitors on the prevention of atherosclerosis, it seems important to start treatment at an earlier stage. The effect of linagliptin, a DPP-4 inhibitor, on cardiovascular outcomes, is currently being investigated in two studies. A meta-analysis study reported that linagliptin does not increase cardiovascular risk 14 . Other studies reported that linagliptin attenuates vascular dysfunction and has direct vasodilatory effects independent of its glucose-lowering properties 15 . Furthermore, linagliptin was reported to have an anti-inflammatory action 15, 16 , and is involved in the suppression of atherosclerosis progression 15 . These data suggest that DPP-4 inhibitors improve glycemic control, and seem to have some cardiovascular protective effect [14] [15] [16] . We hypothesized that linagliptin add-on therapy with metformin can prevent the progression of atherosclerosis and the development of cardiovascular diseases in type 2 diabetes mellitus patients. To test the hypothesis, the present study was carried out to determine the effects of 16-week treatment with linagliptin on endothelial function using FMD and CAVI in type 2 diabetes mellitus patients with moderate hyperglycemia. The present study also compared the effects of add-on linagliptin with those of metformin.
MATERIALS AND METHODS

Study design
The present study, the Randomized Study of Linagliptin Effectiveness on Endothelial Function Assessed by FMD (RELIEF), was a three-arm trial multicenter prospective, randomized open-label, blind end-point study, registered with the University Hospital Medical Information Network Clinical Trial Registry (UMIN000012783), a non-profit organization in Japan that meets the requirements of the International Committee of Medical Journal Editors. The study protocol was approved by the ethics review board of each participating institution. The present study was carried out according to the Declaration of Helsinki and current legal regulations in Japan. The processes of enrollment, randomization, data collection and management were carried out by the third-party entities for data without bias.
Study population
We recruited 96 Japanese patients with type 2 diabetes mellitus who periodically visited the outpatient clinics of 11 institutions in Japan listed in the Supporting Information. The inclusion criteria were as follows: (i) type 2 diabetes mellitus patients treated with metformin 750 mg/day or metformin 750 mg/day and another oral hypoglycemic agent (allowed dose for glimepiride was ≤2 mg/day, glimicron ≤40 mg/day) for at least 12 weeks, in addition to diet and physical therapy; (ii) hemoglobin A1c (HbA1c; National Glycohemoglobin Standardization Program) ≥6.0%, but <8.0%; (iii) age ≥20 and <80 years; (iv) patients who were willing to follow the instructions for drug intake; and (v) patients who gave written informed consent. The exclusion criteria were as follows: (i) patients with type 1 diabetes mellitus or a diabetic condition induced by other disease; (ii) patients treated with thiazolidinediones, DPP-4 inhibitors, sodium-glucose cotransporter 2 inhibitors, insulin or incretin-based drugs within 12 weeks before signing the informed consent; (iii) patients treated with more than 750 mg/day of metformin; (iv) patients who started to use/ change their dose of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, statins or antiplatelet drugs within 12 weeks before signing the informed consent; (v) patients with severe infectious disease, perioperative or severe trauma; (vi) patients with a history of myocardial infarction, angina pectoris, cerebral stroke or cerebral infarction within 12 weeks before signing informed consent; (vii) patients with atrial fibrillation, frequent atrial or ventricular extrasystoles; (viii) patients with moderate or severe heart failure (New York Heart Association stage III or more severe); (ix) Ankle Brachial Pressure Index <0.9; (x) patients with severe liver dysfunction or compromised renal function; (xi) patients with systolic blood pressure >150 mmHg, labile hypertension or labile hyperlipidemia; (xii) patients with alcohol or drug dependence; (xiii) female patients who were pregnant, lactating or possibly pregnant and those planning to become pregnant; (xiv) patients with a history of hypersensitivity to investigational drugs; and (xv) patients whom their physician considered to be ineligible for this study.
Randomization and study intervention
Participants were enrolled and randomly assigned in equal numbers into three groups as follows: control group, metformin group and linagliptin add-on group. The randomization was carried out by a computer-based dynamic allocation system with minimization procedure to balance for sex and with/without administration of statins. After the enrollment, all patients were observed for 4-6 weeks, representing the screening period, and in principle they were not permitted to change the dose of concomitant drugs or add any other drugs, such as other antidiabetic agents, antihypertension drugs, and lipid-lowering and antiplatelet agents. Four weeks or more after the enrollment, blood and urine samples were collected, and FMD and CAVI were measured (baseline data). After baseline data collection, the assigned therapies were started as follows: patients of the control group continued their therapy with metformin 750 mg/day throughout the study period. The dose of metformin in patients of the metformin group was doubled to 1,500 mg/day. Patients of the linagliptin add-on group were treated with metformin 750 mg/day plus linagliptin 5 mg/day. The assigned treatment was continued for 16 weeks (duration of the study). The starting day represented the day of blood/ urine collection for the control group; the day on which the dose of metformin was increased to 1,500 mg/day for the metformin group; and the day of addition of linagliptin for the linagliptin add-on group.
Observation items and schedule
Clinical assessment and data collection were carried out at baseline and 16 weeks after the start date. All FMD and CAVI were carried out at Toho University Omori Medical Center, Tokyo, Japan. The collected blood and urine samples were sent to a central laboratory (SRL Laboratory, Tokyo, Japan) for the measurement of HbA1c, fasting plasma glucose, C-peptide, total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, apolipoprotein A-I/A-II/B/C-II/C-III/E, high-sensitivity C-reactive protein (hs-CRP), adiponectin, urinary 8-hydroxy-2'-deoxyguanosin (8-OHdG) and urinary albumin. 
Study outcomes
FMD
The FMD was measured at baseline and 16 weeks by experienced technicians, using the technique described by the International Brachial Artery Reactivity Task Force 17 and the report of Takeno et al. 17, 18 The measurement was carried out using the UNEX EF38G (UNEX Corporation, Nagoya, Japan) after at least 10 h fasting and under no-smoking condition. After resting more than 15 min at room temperature (25°C), the cuff was applied on the forearm and inflated to acquire images of the brachial artery in the relaxed state using high-resolution ultrasound. After capturing baseline images, the cuff was inflated to 50 mmHg above the systolic blood pressure for 5 min to occlude the brachial artery. Then, the cuff was deflated and the image of the brachial artery was captured. The diameter of the brachial artery was measured on the pre-and post-hyperemia images to determine changes in %FMD (FMD [%] = [maximum diameter -diameter at rest] 9 100 / diameter at rest). The average FMD coefficient of variation was sufficiently small; indicating reproducibility of the FMD measurements.
CAVI CAVI and the ankle brachial index were measured by experienced technicians at baseline and 16 weeks using VaSera VS-1500 (Fukuda-Denshi Company, Tokyo, Japan), and the method of measurement as described in detail previously 5, 19, 20 . Briefly, the participant fasted for at least 10 h. While lying in the supine position, the cuffs were applied to both the upper arm and ankle, and the electrocardiogram and heart sound were monitored. After the 10-min equilibration period, the pulse wave velocity (PWV) between the heart and ankle was measured by L/T, where L is the distance from the aortic valve to the ankle, and T is the time taken for the pulse wave to propagate from the aortic valve to the ankle. The brachial and ankle pulse waves were detected with cuffs that are also used for measurement of blood pressure. The PWV was converted to CAVI digitally using the following formula: CAVI = a([2q/ DP] 9 In[Ps/Pd] 9 ba-PWV 2 ) + b, where q is blood density, Ps and Pd are systolic blood pressure and diastolic blood pressure, respectively, ba-PWV is the brachial-ankle pulse wave velocity measured between the aortic valve and the ankle, and a and b are constants. The average CAVI coefficient of variation was less than 5%, indicating the reproducibility of CAVI.
Biochemical tests
The following procedures/methods were applied: latex agglutination for HbA1c: chemiluminescence enzyme immunoassay for insulin, C-peptide and adiponectin; hexokinase ultraviolet method for blood glucose level; ultraviolet method with cholesterol dehydrogenase for total cholesterol; enzymatic method (glycerol phosphate oxidase peroxidase method without free glycerol) for triglyceride; direct method for HDL and LDL cholesterol; immunoturbidimetric method for apolipoproteins; nephelometry for hs-CRP; and high-performance liquid chromatography for 8-OHdG.
Safety and evaluation of adverse events
All adverse events observed during the study were recorded. When these were considered serious, they were reported immediately to the respective institution, the principal investigator and the administration office.
Sample size
We assumed difference in the primary end-point of DFMD at 2.0 -2.3%, based on previous studies 21, 22 . Based on a two-sided P-value of 5% and a power of 80%, the number of cases required to detect a significant difference was estimated to be 22 cases per group. Assuming a dropout rate of 30%, the target number of enrolled patients was set to 32 cases per group for a total of 96 cases.
Statistical analysis
Analyses were carried out on the full analysis set (FAS) under an intention-to-treat approach, except for safety analysis with adverse events, which was carried out on the treated set. The FAS included all patients who showed changes in FMD at week 16, whereas the treated set included all patients who had some data on safety evaluation at week 16 ), HbA1c at baseline (<7/≥7%) and change in HbA1c (<median/≥median). We also carried out simple and multiple linear regression analyses with DFMD as the dependent variable after single linear regression analysis. Simple regression analysis was carried out with each of all items (clinical parameters at baseline and changes at end of study, and background variables) as the independent variable. Multiple linear regression analysis was carried out with the following independent variables: age, sex and all variables with a P-value of regression coefficient in the simple regression analysis of <0.1. In order to avoid multicollinearity, we calculated the variance inflation factor and chose one variable from the correlated variables. All statistical analyses were carried out on SAS 9.3 (SAS Institute Inc., Cary, NC, USA) under instruction of an independent biostatistician.
RESULTS
Differences between the participants of the three groups A total of 96 patients were enrolled in the study between January 2014 and March 2015, and randomized to the three groups (Figure 1 ). At the end of the study, the FAS included 29, 26 and 29 patients in the control group, metformin group and linagliptin add-on group, respectively. The baseline clinical characteristics of the patients are shown in Table 1 . As significant differences were detected in diastolic blood pressure and the use of a-glucosidase inhibitor (P < 0.05, each) among the three groups, we applied multiple comparisons for these two variables. The results showed that only diastolic blood pressure was significantly different between the control and linagliptin groups. There were no differences in all the clinical characteristics, except for diastolic blood pressure, among the three groups.
Significant improvement in FMD in the linagliptin add-on group Table 2 and Figure S1 show the FMD values at baseline, week 16 and the DFMD values. DFMD value was significantly better in the linagliptin add-on group (P < 0.05), but not in the other two groups. FMD were not different among the three groups at baseline, week 16 and DFMD. Subgroup analyses for DFMD showed that FMD improved significantly only in the linagliptin add-on group, with HbA1c <7.0% at baseline (P < 0.05; Table 2 ). Table S1 shows the results of CAVI. No significant differences were observed at baseline, week 16, and DCAVI in the same group and among the groups. CAVI improved significantly in only the linagliptin add-on group in patients aged <65 years at baseline (Table S1 ). In addition, patients of the linagliptin addon group with BMI ≥25 kg/m 2 at baseline showed significant improvement in CAVI compared with the metformin group.
CAVI and other clinical parameters
Improvement of HbA1c in the metformin and linagliptin addon groups, whereas insulin resistance improves only in the metformin group HbA1c improved significantly in both the metformin group and the linagliptin add-on group (P < 0.01 and P < 0.001, respectively; Table 3 ). Notably, the mean baseline HbA1c was <7% in the participants of the present study. Significant differences were also detected in HbA1c at week 16 and the DHbA1c among the three groups. Fasting plasma glucose was significantly reduced only in the linagliptin add-on group (P < 0.001), but not the other two groups (Table 3) . C-peptide and HOMA-IR were significantly reduced only in the metformin group (P < 0.05, each; Table 3 ). Tables S2 and S3 show changes in clinical parameters related to atherosclerosis and cardiovascular events, such as lipid metabolism, inflammation, oxidative stress and urinary albumin. Total cholesterol at week 16 and the delta change were significantly different among the three groups (P < 0.01, each; Table S2 ). The Dtotal-cholesterol was significantly larger in the control group and lower in the linagliptin add-on group. HDL cholesterol was significantly reduced in the metformin group, and the Dchange in this parameter was significantly different among the three groups. The Dchange in LDL cholesterol was significantly different among the three groups. Apolipoprotein A-I was significantly reduced in both the metformin and linagliptin add-on groups (P < 0.05, each), and the Dchange in this variable was also significantly different among the three groups. Apolipoprotein A-II increased in the control group, and Dapolipoprotein A-II was significantly different among the three groups. The apolipoprotein B level at week 16 and Dapolipoprotein B were significantly different among the three groups (P < 0.05, each), and apolipoprotein B was significantly reduced only in the linagliptin add-on group (P < 0.01). Apolipoprotein C-III at week 16 was significantly different among the three groups, and was significantly reduced only in the metformin group. Apolipoprotein E was significantly reduced only in the linagliptin add-on group. No significant changes were observed in hs-CRP, adiponectin, 8-OHdG and urinary albumin at the end of the study in any group, and the Dchanges were not significantly different among the groups (Table S3) .
Significant reduction in apolipoprotein B in the linagliptin add-on group
Association of DFMD with DApolipoprotein B, baseline FMD and sex Simple regression analyses were carried out between DFMD as the dependent variable and each of the evaluated factors as independent variables. Significant regression coefficient was detected for seven independent variables (Table S4) . Multiple linear regression analysis that included the aforementioned variables identified Dapolipoprotein B (b = -0.0507, P < 0.05), FMD at baseline (b = -0.7890, P < 0.001) and sex (b = 1.2295, P < 0.05) as significant associations with DFMD (Table 4) . Table S5 lists the reported/observed adverse events during the study. The observed adverse events per groups were one for the control group, four for the metformin group and one for the linagliptin add-on group. There was no significant difference in the incidence of adverse events among the groups.
Adverse events
Only a single serious adverse event was noted in the present study; pancreatic cancer in a patient of the metformin group.
DISCUSSION
Treatment of type 2 diabetes mellitus encompasses two important goals; adequate glycemic control, and prevention of complications including atherosclerosis and cardiovascular events. The main result of the present study was the beneficial effects of linagliptin add-on therapy compared with those of metformin in Japanese type 2 diabetes mellitus patients with moderate hyperglycemia. Although there was no significant difference among the three groups, only linagliptin add-on therapy for 16 weeks significantly improved endothelial function, as reflected by FMD.
A subpopulation analysis based on baseline HbA1c (using a cut-off value of 7%) found conspicuous improvement in FMD in patients of the linagliptin add-on group with low baseline HbA1c level (Table 2 ). This finding shows that linagliptin could potentially improve endothelial function in the earlier stage of type 2 diabetes mellitus. Another subanalysis based on DCAVI also showed significant reduction in CAVI in patients of the linagliptin add-on group aged less than 65 years, compared (Table S1 ). Although improvement of CAVI by linagliptin was obvious in participants of young age and high BMI, interestingly, an increase of DFMD by linagliptin was observed in old age and low BMI (Table 2 ). According to previous reports, no association was observed between CAVI and FMD 23, 24 . These data might partially explain the discrepancy between FMD and CAVI change in the linagliptin add-on group. Linagliptin seems to be more effective in patients with low HbA1c and young age with high BMI with regard to the prevention of atherosclerosis. These findings suggest that treatment with linagliptin is more beneficial than metformin Data are expressed as mean -standard deviation or number of patients (%). P-values are results of ANOVA or Kruskal-Wallis test for continuous data, and Fisher's exact test for categorical data; when significant difference was detected, multiple comparisons were applied, the results of which are marked by superscripts as follows: † P < 0.05 versus the control group; ‡ P < 0.05 versus the linagliptin add-on group. ACE inhibitor, angiotensin-converting enzyme inhibitor; BMI, body mass index; DBP, diastolic blood pressure; EPA, eicosapentaenoic acid; HbA1c, hemoglobin A1c; NGSP, National Glycohemoglobin Standardization Program; SBP, systolic blood pressure. supplementation in terms of the suppression of atherosclerosis progression. We used metformin therapy as the control because it is one of the most widely used oral antidiabetic agents for type 2 diabetes mellitus 9, 10 , and is known to prevent cardiovascular events 8 . In addition, because insulin resistance is considered to be involved in the pathogenesis of cardiovascular disease, metformin, which improves whole-body insulin resistance, is considered to prevent cardiovascular disease 8, 25 . In fact, increasing the dose of metformin from 750 to 1,500 mg/day resulted in improvement in HOMA-IR, which was specifically observed in the metformin group (Table 3) . However, although HbA1c improved in both the metformin and linagliptin add-on groups, and HOMA-IR was significantly improved in the metformin group, improvement in FMD was observed only in the linagliptin add-on group. This shows not only improvement in glycemic control and insulin resistance, but that other factors also contribute to the improvement in FMD in the linagliptin add-on group. In this regard, linagliptin add-on therapy had a beneficial effect in patients with a baseline HbA1c of <7.0%.
To elucidate the factors associated with DFMD, simple and multiple linear regression analyses were carried out. The results of multiple linear regression analysis showed Dapolipoprotein B, FMD at baseline and sex as significant factors associated with DFMD (Table 4) . Of these three factors, only apolipoprotein B changed significantly in the linagliptin add-on group, but not in the other two groups (Table S2 ). There were no differences in the other two factors among the groups. These findings suggest that linagliptin add-on therapy improves vascular endothelial function by reducing apolipoprotein B. Multiple linear regression analysis was carried out with the following parameters as independent variables: age at baseline, sex and variables with P-values of single regression analysis of <0.1. To avoid the multicollinearity, one variable from correlate variables was selected and the variance inflation factor was calculated. FMD, flow-mediated dilation; SE, standard error.
Apolipoprotein B is known to interact with very low-, intermediate-and low-density lipoproteins as well as chylomicrons 26, 27 , and is also known as a predictor of cardiovascular disease 28 . A previous clinical trial of fenofibrate in type 2 diabetes mellitus patients showed that Dapolipoprotein B48 was associated with DFMD
29
. Glucagon-like peptide-1 is known to repress intestinal apolipoprotein B production and triglyceride in rats 30 , thus DPP-4 inhibitors are also expected to reduce apolipoprotein B and triglyceride through glucagon-like peptide-1 activation. In fact, it has been reported that sitagliptin decreased postprandial triglyceride and apolipoprotein B48 levels 31 , and that vildagliptin also reduced apolipoprotein B and lipids in postprandial plasma, but not in a fasting situation 32 . As the blood tests were carried out in the fasting state in the present study, it is possible that no reduction in triglyceride was detected in linagliptin add-on therapy despite the reduction in apolipoprotein B under fasting conditions.
To date, other beneficial effects of DPP-4 inhibitors on atherosclerosis have been reported, together with their potential mechanisms. DPP-4 inhibitors lower postprandial glucose. This is important, as postprandial hyperglycemia is an independent risk factor of atherosclerosis 3, 33 . In the present study, it is possible that the reduction of postprandial glucose might have played a role in the observed improvement in FMD. Treatment with DPP-4 inhibitors is also known to reduce inflammatory markers, such as hs-CRP and tumor necrosis factor-a, and increase anti-inflammatory markers, such as cytokine interleukin-10 and adiponectin [34] [35] [36] . In the present study, no changes were observed in hs-CRP and adiponectin (Table S3) . However, one cannot exclude changes in other inflammatory cytokines that were not measured in the present study, such as tumor necrosis factor-a, intercellular adhesion molecules 1 and endothelial factors, such as vascular cell adhesion protein 1, with subsequent effects on endothelial function. Thus, further investigation is required to elucidate the mechanisms underlying the improvement in endothelial function after treatment with DPP-4 inhibitors.
Although the present study showed the positive effects of linagliptin on endothelial function, it had several limitations. First, this was an open-label design study with a relatively small number of Japanese patients, so additional long-term trials of larger sample size, preferably of patients of different ethnicities, are required to address the cardiovascular benefits of linagliptin. Second, total apolipoprotein B was measured rather than apolipoprotein B48 and B100 separately. Accordingly, we cannot discuss separately or conclude which type plays a role in the observed changes. Third, detailed lipid profiling was not carried out. Accordingly, we could not estimate the effect of linagliptin on various lipids, such as very lowdensity lipoprotein and chylomicrons. Fourth, all measurements were carried out using fasting plasma samples. Previous studies showed clear effects for DPP-4 inhibitor on the postprandial state 32 .
In conclusion, the present study showed the potential effectiveness of metformin plus linagliptin treatment in type 2 diabetes mellitus patients with moderate hyperglycemia, by inducing both better glycemic control and improvement of endothelial function.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article: Figure S1| Changes in flow-mediated dilation during the 16-week study. 
